Provided by Tiger Trade Technology Pte. Ltd.

MaxCyte Inc

0.7674
+0.00720.95%
Post-market: 0.7672-0.0002-0.03%16:56 EST
Volume:965.34K
Turnover:735.97K
Market Cap:81.86M
PE:-1.78
High:0.7796
Open:0.7524
Low:0.7450
Close:0.7602
52wk High:3.58
52wk Low:0.6434
Shares:106.67M
Float Shares:96.17M
Volume Ratio:0.76
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4299
EPS(LYR):-0.3916
ROE:-23.19%
ROA:-13.66%
PB:0.45
PE(LYR):-1.96

Loading ...

BRIEF-MaxCyte Q3 Gross Profit USD 5.2 Million

Reuters
·
Nov 13, 2025

MaxCyte Q3 Net Income USD -12.4 Million

THOMSON REUTERS
·
Nov 13, 2025

Press Release: MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Dow Jones
·
Nov 13, 2025

MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance

Benzinga
·
Nov 05, 2025

Gene therapy firm MaxCyte misses Q3 revenue estimates

Reuters
·
Nov 05, 2025

MaxCyte reports preliminary Q3 revenue $6.8M, consensus $8.37M

TIPRANKS
·
Nov 05, 2025

BRIEF-MaxCyte Q3 Revenue USD 6.4 Million Vs. IBES Estimate USD 8.37 Million

Reuters
·
Nov 05, 2025

MaxCyte Delays Third Quarter Financial Results Release

Reuters
·
Nov 05, 2025

MaxCyte - Reiterates 2025 Revenue Guidance for Core Business Revenue and Spl Program-Related Revenue

THOMSON REUTERS
·
Nov 05, 2025

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

GlobeNewswire
·
Nov 05, 2025

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

GlobeNewswire
·
Oct 08, 2025

MaxCyte Signs Strategic Platform License Agreement with Moonlight Bio for T Cell Therapy Development

Reuters
·
Oct 06, 2025

MaxCyte Announces Strategic Platform License Agreement With Moonlight Bio to Advance T Cell Therapies for Solid Tumors

THOMSON REUTERS
·
Oct 06, 2025

MaxCyte Inc - Moonlight Bio to Use MaxCyte Technology for T Cell Therapy

THOMSON REUTERS
·
Oct 06, 2025

MaxCyte Announces Major Workforce Reduction Plan

TIPRANKS
·
Sep 23, 2025

BRIEF-Maxcyte Announces Operational Restructuring To Reduce Costs

Reuters
·
Sep 23, 2025

MaxCyte Inc. Announces 34% Workforce Reduction in Strategic Restructuring to Cut Costs and Boost Profitability

Reuters
·
Sep 23, 2025

MaxCyte Inc - Expects 2025 Core Revenue Flat to Down 10%

THOMSON REUTERS
·
Sep 23, 2025

MaxCyte Inc - to Reduce 34% of Global Workforce

THOMSON REUTERS
·
Sep 23, 2025

MaxCyte Inc - Expects $13.6 Mln in Annualized Savings From Restructuring

THOMSON REUTERS
·
Sep 23, 2025